EU/EEA · Phase III-containing · Immune-mediated dermatology
EU Phase III hidradenitis suppurativa benchmark: sites, PIs and adjacent dermatology experience
University of Debrecen leads the broader Phase III dermatology site network with 17 trial participations, while Andrea Szegedi leads investigator experience with 16. Both also participated in all three Phase III studies in the cohort that include hidradenitis suppurativa.
Top 5 sites · Adjacent inflammatory dermatology
University of Debrecen leads with 17 Phase III trial participations
Charité and Royalderm follow with 14 each. Klinika Ambroziak and Provita complete the top five with 13 each.
Hidradenitis suppurativa
3 Phase III studiesOne also includes other povorcitinib indicationsUniversity of Debrecen, Charité, Klinika Ambroziak, Provita and Thermalsole Bad Bentheim participated in all three HS studies. Their broader late-stage dermatology experience ranges from 13 to 17 trials.
Trial participation shows relevant late-stage experience, not current recruitment capacity or site performance.
Top 5 investigators · Adjacent inflammatory dermatology
Andrea Szegedi leads investigator experience with 16 trials
Athanasios Tsianakas follows with 15 and Witold Owczarek with 14. Nina Magnolo has participated in 11, while Anita Lewartowska-Białek has participated in 10.
Hidradenitis suppurativa
Repeated HS participationAcross the three Phase III studiesAndrea Szegedi and Athanasios Tsianakas participated in all three HS studies and also lead the broader benchmark with 16 and 15 trials. Anita Lewartowska-Białek also participated in all three and has contributed to 10 broader Phase III dermatology trials.
Top 5 country footprints · Adjacent inflammatory dermatology
Poland and Germany participate in 23 of 24 trials
Among the five most frequently selected markets, Poland carries the largest median planned country allocation at 89 participants, followed by Germany at 42.5.
Hidradenitis suppurativa
10 countries in all 3DE, FR, IT, PL, ES, BG, HU, BE, CZ, NLGermany, France and Italy each carry a median planned allocation of 37 participants across the three HS studies. Poland and Spain follow at 35.
Country figures are planned recruitment allocations, not completed enrollment. Country allocations can exceed the final global sample size when summed.
Top 5 CROs · Adjacent inflammatory dermatology
ICON leads operational support across six programs
Excelya and Syneos Health each support three programs. Optimapharm and Parexel complete the top five with two each.
Hidradenitis suppurativa
Operational experienceAcross the three Phase III studiesICON supports two of the three HS studies. PRA Hellas contributes to one.
CRO participation shows relevant operational experience, not CRO quality or performance.
Source: CTIS trial entries, country recruitment plans and trial documents, reviewed 19 September 2026. The main cohort covers 24 Phase III-containing European trials across hidradenitis suppurativa and six adjacent immune-mediated dermatology indications: atopic dermatitis, plaque psoriasis, chronic spontaneous urticaria, prurigo nodularis, alopecia areata and vitiligo. The HS focus covers three Phase III studies that include hidradenitis suppurativa, including one multi-indication rollover study.